Hepatitis B virus-specific (HBV-specific) T cells have been identified as main effector cells in HBV clearance. In contrast, B cells producing neutralizing antibodies against the HBV surface antigen (HBsAg) have been studied in little detail, mainly due to methodical limitations. In this issue of the JCI, two reports use a new technique to specifically detect and characterize HBsAg-specific B cells ex vivo. Indeed, these cells are present, but show phenotypic alterations and impaired function during acute and chronic HBV infection. Thus, HBsAg-specific B cells are a novel attractive target for antiviral strategies toward functional cure of chronic HBV infection.
A fourth of the world's population has been infected with hepatitis B virus (HBV), and an estimated 250 million people are chronically infected, putting them at risk for progressive liver disease, liver cirrhosis, liver failure, and hepatocellular carcinoma. Of adults infected with HBV, 95% clear the virus spontaneously, while 90% of newborns develop chronic infection. Since HBV infection does not induce an interferon response, HBV is a stealth virus with respect to the innate immune system (1, 2) . Therefore, HBV clearance depends on a successful adaptive immune response. Indeed, a multispecific and vigorous HBV-specific CD8 + T cell response has been associated with viral clearance (3, 4) , while HBV-specific CD8 + T cell exhaustion is a hallmark of persistent infection (5) (6) (7) . Less attention, however, has been paid to the role of neutralizing antibodies targeting the envelope protein of HBV, the HBV surface antigen (HBsAg). Indeed, the hepatitis B surface antibody (anti-HBs) is only detectable in the blood of HBV-infected individuals after the loss of HBsAg, either upon the resolution of acute infection or in case of the rare event of spontaneous or drug-induced clearance of chronic HBV infection. Thus, anti-HBs is seen as not playing a major role in HBV clearance. Anti-HBs, on the other hand, has been established as a diagnostic tool, indicating protective immunity after acute-resolving HBV infection or vaccination as well as "functional cure" of chronic HBV infection (HBsAg to anti-HBs seroconversion). There are, however, several clinical observations that argue against such a minor role of anti-HBs. First, antiHBs contained in hepatitis B immunoglobulin (HBIG) is well known to prevent vertical HBV transmission from infected mothers to newborns as well as reinfection of liver transplants in previously HBVinfected hosts. Second, B cell-depleting drugs used in oncology and rheumatology, such as the anti-CD20 antibody rituximab, induce HBV reactivation in HBV carriers and even in patients with "resolved" HBV in whom nuclear HBV cccDNA persists as a viral reservoir for decades (8) . These clinical observations indicate that antiHBs has a more prominent role than previously acknowledged. Indeed, anti-HBs can block HBV cell entry, either by blocking the binding site of HBsAg for the cell receptor recently identified to be sodium taurocholate cotransporting polypeptide (NTCP) or by binding to the "antigenic loop" of HBsAg that is involved in interaction with heparan sulfate proteoglycan (HSPG) in a prereceptor step of cell entry. In addition to direct inhibition of cell entry, anti-HBs also mediate endocytosis and subsequent neutralization of virions as well as Fc-mediated phagocytosis and killing of infected cells. In addition, anti-HBs, HBsAg, and additional components build immune complexes that can activate HBVspecific T cells (9) .
HBsAg-specific B cells in acute and chronic HBV infection
Given these important antiviral functions of anti-HBs, a main open issue in HBV immunobiology is the reason for the lack of detectable anti-HBs in both acute and chronic HBV infection prior to HBsAg loss. To date, two plausible hypothetical explanations for the lack of anti-HBs have been put forth. First, it was suggested that anti-HBs is produced by HBsAg-specific B cells in acute and chronic HBV infection, but is depleted by the large number of circulating HBsAg-containing subviral particles that outnumber complete virions by an order of magnitude. This hypothesis was supported by the finding that complexes of anti-HBs with circulating HBsAg are not recognized by current diagnostic assays, but can be detected in chronically infected patients using highly sensitive immunoassays (10) . Additionally, there were early and have been more recent reports of HBsAg-specific B cell dysfunction, especially in chronic HBV infection. Indeed, B cells isolated from patients with chronic HBV infection showed a reduced proliferative capacity and were not able to produce anti-HBs upon stimulation. This functional defect reverted after the rare event of HBsAg loss during chronic infection (11, 12 (13, 14) or the addition of IL-2, IL-21, and CD40 ligand-expressing (CD40L-expressing) feeder cells (13) .
Opening the doors for B celltargeted research in hepatitis B
These results clearly argue for B cell dysfunction rather than antibody depletion as the main reason for the lack of anti-HBs in acute and chronic HBV infection. the optimal strategy for restoring HBsAgspecific B cell function on the way to functional cure of chronic HBV infection. Of note, PD-1 blockade enhances antiviral B cell immunity against SIV in macaques in vivo (20) . Specifically, it will be important to identify the best intervention for the restoration of B cell function, e.g., targeting of single versus multiple inhibitory receptors or choice of the most promising cytokine and feeder cell to be used in vivo and/or for adoptive cell transfer. With these important questions and exciting opportunities, HBsAg-specific B cells are expected to be in the spotlight for the next several years.
